Search

Polysaccharide monooxygenases, or PMOs (also known as lytic PMOs or LPMOs), are a group of enzymes discovered in recent years to catalyze the oxidative degradation of carbohydrate polymers. The PMO catalytic domain has a β-sandwich fold that bears a strong resemblance to both immunoglobulin (Ig) and fibronectin type III (FnIII) domains. PMOs are secreted by fungi and bacteria, and there is recent evidence for their roles in pathogenesis, in addition to biomass processing. This review addresses the biological origins and functions of emerging PMO families, as well as describes the aspects of PMO structure that support the chemistry of copper-catalyzed, oxidative polysaccharide degradation., (Copyright © 2015 Elsevier Ltd. All rights reserved.)

Conformationally restricted arginine analogues (1-5) were synthesized and found to be alternative substrates or inhibitors of the three isozymes of nitric oxide synthase (NOS). A comparison of k(cat)/Km values shows that (E)-3,4-didehydro-D,L-arginine (1) is a much better substrate than the corresponding (Z)-isomer (2) and 3-guanidino-D,L-phenylglycine (3), although none is as good a substrate as is arginine; 5-keto-D,L-arginine (4) is not a substrate, but is an inhibitor of the three isozymes. Therefore, it appears that arginine binds to all of the NOS isozymes in an extended (E-like) conformation. None of the compounds exhibits time-dependent inhibition of NOS, but they are competitive reversible inhibitors. Based on the earlier report that N(omega)-propyl-L-arginine is a highly selective nNOS inhibitor (Zhang, H. Q.; Fast, W.; Marletta, M.; Martasek, P.; Silverman, R. B. J. Med. Chem. 1997, 40, 3869), (E)-N(omega)-propyl-3,4-didehydro-D,L-arginine (5) was synthesized, but it was shown to be weakly potent and only a mildly selective inhibitor of NOS. Imposing conformational rigidity on an arginine backbone does not appear to be a favorable approach for selective NOS inhibition.

N omega-Propargyl-L-arginine (7) was synthesized as a potential mechanism-based inactivator of neuronal nitric oxide synthase (nNOS) and macrophage nitric oxide synthase (iNOS). Compound 7 is a potent reversible competitive inhibitor for both isoforms, having Ki values of 430 +/- 50 nM and 620 +/- 30 nM for nNOS and iNOS, respectively. These values are 12 and 32 times lower than the K(m) for L-arginine with nNOS and iNOS, respectively; however, 7 does not exhibit time-dependent inhibition with either. It also only undergoes oxidation very slowly. N omega-Hydroxy-N omega-propargyl-L-arginine also was synthesized to determine if the initial proposed enzyme-catalyzed hydroxylation of N omega-propargyl-L-arginine was problematic. This compound also is a potent reversible inhibitor of both nNOS and iNOS, but is not a time-dependent inactivator and is oxidized only very slowly. These results are in sharp contrast with the corresponding olefins, N omega-allyl-L-arginine and N omega-allyl-N omega-hydroxy-L-arginine recently reported to be potent time-dependent, irreversible inhibitors of nNOS (Zhang, H. Q.; Dixon, R. P.; Marletta, M. A.; Silverman, R. B., J. Am. Chem. Soc. 1997, 119, in press); N omega-allyl-L-arginine also was reported to be an inactivator of iNOS (Olken, N. M.; Marletta, M. A. J. Med. Chem. 1992, 35, 1137). This suggests that the active site of both isoforms of NOS can accommodate a variety of structures, but binding must have the appropriate juxtaposition for hydroxylation; otherwise, no oxidation occurs.